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Background: Growth factors play important roles in wound 
healing. However, the evidence for the effects of growth fac-
tors on post-thyroidectomy scars is limited. Objective: We 
performed a prospective study to assess the preventive and 
therapeutic effect of a multi-growth factor (MGF)-containing 
cream on post-thyroidectomy scars. Methods: Twenty-one 
patients with thyroidectomy scars applied MGF cream twice 
a day. We assessed the changes in erythema, pigmentation, 
skin elasticity, and skin hydration status using the erythema 
index, melanin index, cutometer, and corneometer, res-
pectively. In addition, Vancouver scar scale (VSS) and patient 
satisfaction were assessed at 10 days after surgery (baseline), 
2 weeks, 6 weeks, and 12 weeks after baseline. Results: The 
mean total VSS scores were significantly lower at 6 weeks 
(3.24±1.51 vs. 1.91±1.38) and 12 weeks (3.24±1.51 vs. 
1.71±1.59) compared to the baseline. The degree of pig-
mentation was significantly lower at 12 weeks compared to 
the baseline, and the skin elasticity, and the skin hydration 
status were significantly higher at 12 weeks compared to the 
baseline. Over 85% of the patients were satisfied with the use 
of MGF cream without any adverse effect. Conclusion: MGF 
cream might have additive or supportive effect for scar for-





Thyroid cancer is the most common type of cancer diag-
nosed in South Korea. More than 40,000 people in the 
country were diagnosed with the disease in 20111. Thyroid 
cancer is also increasing dramatically in United States. 
Over 40,000 new cases of thyroid cancer were diagnosed 
in the United States in 2010 and the average annual per-
centage changes in incidence are 5.4% in men and 6.5% 
in women, suggesting that this cancer will be the fourth 
leading cancer diagnosed by 2030 in United States2. In 
the patients diagnosed with thyroid cancer, completeness 
of surgical resection is an important determinant of 
outcome. Thus the most of the patients are treated with 
thyroidectomy with central compartment neck dissection 
(CCND) or modified radical neck dissection, although 
small tumors that have not spread outside the thyroid 
gland may be treated by lobectomy3. 
Surgical treatments inevitably remain scars, and thyroid 
surgery especially makes scar on neck. Scar on neck easily 
shows hypertrophy due to its inevitable many movements 
and stretching4. And it is easily noticed by the people due 
to its location and consequently causes many cosmetic 
problems. Thus it is increasingly important to prevent or 
minimize scar changes in patients who underwent thy-
roidectomy. 
Wound healing is a complex process involving many 
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cells, cytokines, and growth factors. Growth factors, such 
as epidermal growth factor (EGF), and fibroblast growth 
factor (FGF), platelet-derived growth factor (PDGF), vas-
cular endothelial growth factor (VEGF), play important 
roles in wound healing4. However, the evidence for the 
effects of growth factors on post-thyroidectomy scars is 
limited. In this study, we performed a prospective study to 
assess the preventive and therapeutic effect of a mul-




Patients with thyroid carcinoma who underwent open to-
tal thyroidectomy with CCND between January 2015 and 
July 2015 were enrolled in this study. A 5- to 7-cm cer-
vical collar incision was made, and subplatysmal flap dis-
section was performed from the sternal notch inferiorly to 
the thyroid cartilage superiorly and laterally to both me-
dial borders of the sternocleidomastoid muscle.
This study was approved by the Institutional Review 
Board of Severance Hospital, Yonsei University (IRB no. 
4-2014-0892), and written and informed consent was ob-
tained from each patient. Exclusion criteria included a his-
tory of keloid scarring and any other scar preventive cos-
metic use in the 3 months prior to treatment. 
Study design 
The patients applied MGF cream twice a day. The MGF 
cream contained multiple growth factors, such as PDGF, 
VEGF, EGF, and FGF with humectant and emollient (PDGF 
and VEGF, EGF and FGF, 1.5% weight of mixture).
All patients were assessed the changes in post-thyroi-
dectomy scar status after applying MGF cream at 10 days 
after surgery (baseline), 2 weeks, 6 weeks, and 12 weeks 
after baseline. During the follow-up period, patients were 
prohibited from using any oral or topical medication, ex-
cepting the creams used in this study.
Evaluation
Photographs were obtained using identical digital camera 
settings, lighting conditions, and patient positioning at the 
first visit before applying MGF cream, as well as at the 
second visit (2 weeks after baseline), third visit (6 weeks 
after baseline), and fourth visit (12 weeks after baseline). 
Melanin indices and erythema indices were measured to 
assess the degree of pigmentation and erythema with a 
MexameterⓇ MX 18 connected to the Multiprobe Adapter 
System (Courage Khazaka Electronic GmbH, Köln, Germany) 
and at each follow-up visit. The degree of skin elasticity 
was measured with a CutometerⓇ dual MPA 580 (Courage 
Khazaka Electronic GmbH) and the degree of skin hydra-
tion was measured with a CorneometerⓇ CM825 (Courage 
Khazaka Electronic GmbH) at every follow-up visit. Pa-
tients maintained comfortable supine positon during the 
measurements and the assessment was done at the labo-
ratory which maintaining constant temperature and hu-
midity. The probe was always held perpendicular and 
maintained firm contact to the scar tissue to be assessed. 
At every visit, physicians graded the post-thyroidectomy 
scar status using the Vancouver scar scale (VSS)5, which 
includes pigmentation (0, normal; 1, hypopigmented; 2, 
mixed pigmentation; 3, hyperpigmented), vascularity (0, 
normal; 1, pink; 2, red; 3, purple), pliability (0, normal; 1, 
supple; 2, yielding; 3, firm; 4, banding; 5, contracture), 
and height (0, flat; 1, ≤2 mm; 2, 2∼5 mm; 3, ≥5 mm). 
The score for each parameter was assessed separately, and 
then all 4 parameters were combined.
At final visit, patients also scored their overall rates of sat-
isfaction (0=unsatisfied, 1=slightly satisfied, 2=satisfied, 
3=very satisfied), and adverse effects associated with the 
cream including erythema, tingling, scaling, and itching 
were assessed. 
Statistical analysis
Data were compared using the one-way ANOVA test and 
the individual differences were assessed using a Tukey test 
if the ANOVA was significant. All data are presented in 
the form of mean±standard deviation. All statistical analy-
ses were performed using IBM SPSS software ver. 23.0 
(IBM Co., Armonk, NY, USA), with p＜0.05 considered 
statistically significant in all cases.
RESULTS
Patient characteristics
A total of twenty-one East Asian patients who underwent 
open total thyroidectomy with CCND were enrolled in 
this study, and were composed of three males and eight-
een females. The mean age of subjects was 42.19 years 
(range: 28∼56 years) and the mean body mass index was 
23.52±4.00.
Objective assessments
Degree of erythema and pigmentation was evaluated at 
each visit using the erythema index and the melanin 
index. We found no significant differences in erythema in-
dex between the visits. However, the melanin index at 12 
weeks was significantly decreased compared to the base-
line (165.5±48.25 vs. 128.6±29.41; p＜0.05).
The relative elasticity of the surgical scar was assessed 
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Fig. 1. (A∼D) Data from the objective assessments of the patients at every visit. V1: visit 1 (baseline), V2: visit 2 (2 weeks after 
applying multi-growth factor [MGF] cream), V3: visit 3 (6 weeks after applying MGF cream), V4: visit 4 (12 weeks after applying 
MGF cream). *Signifies statistically significant difference (p＜0.05).
Table 1. Objective assessment data of the patients at every visit
　Variable Visit 1 Visit 2 Visit 3 Visit 4
Erythema index 406.6±76.89 373.4±69.96 370.7±69.49 375.0±73.80
Melanin index 165.5±48.25 141.9±26.57 137.2±35.26 128.6±29.41
Cutometer 0.56±0.16 0.62±0.18 0.72±0.14 0.76±0.10
Corneometer 31.60±9.80 57.62±12.29 60.40±11.06 54.71±9.71
Values are presented as mean±standard deviation. V1: visit 1 (baseline), V2: visit 2 (2 weeks after applying multi-growth factor [MGF]
cream), V3: visit 3 (6 weeks after applying MGF cream), V4: visit 4 (12 weeks after applying MGF cream).
at each visit. The cutometer at 6 weeks (0.56±0.16 vs. 
0.72±0.14; p＜0.05) and 12 weeks (0.56±0.16 vs. 
0.76±0.10; p＜0.05) were significantly increased com-
pared to the baseline, and the cutometer at 12 weeks 
(0.62±0.18 vs. 0.76±0.10; p＜0.05) was significantly in-
creased compared to the cutometer at 2 weeks.
The relative skin hydration status was also assessed at 
each visit, and the corneometer at 2 weeks (31.60±9.80 
vs. 57.62±12.29; p＜0.05), 6 weeks (31.60±9.80 vs. 
60.40±11.06; p＜0.05) and 12 weeks (31.60±9.80 vs. 
54.71±9.71; p＜0.05) were significantly increased com-
pared to the baseline (Table 1, Fig. 1).
Vancouver scar scale score
The severity of the post-thyroidectomy scars were assessed 
using VSS and is summarized in Table 2 and Fig. 2. The 
mean total VSS scores were significantly lower at 6 
weeks (3.24±1.51 vs. 1.91±1.38; p＜0.05) and 12 weeks 
(3.24±1.51 vs. 1.71±1.59; p＜0.05) compared to the 
baseline. Photographs of representative patients are shown 
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Table 2. Vancouver scar scale score of the patients at every visit
 Variable Visit 1 Visit 2 Visit 3 Visit 4
Pigmentation 0.76±0.94 0.19±0.68 0.05±0.22 0
Vascularity 1.14±0.36 0.91±0.44 0.81±0.40 0.76±0.44
Pliability 1.10±0.54 1.10±0.83 0.81±0.87 0.67±0.91
Height 0.24±0.44 0.14±0.36 0.24±0.44 0.29±0.56
Total score 3.24±1.51 2.43±1.66 1.91±1.38 1.71±1.59
Values are presented as mean±standard deviation. V1: visit 1 (baseline), V2: visit 2 (2 weeks after applying multi-growth factor [MGF]
cream), V3: visit 3 (6 weeks after applying MGF cream), V4: visit 4 (12 weeks after applying MGF cream).
Fig. 2. (A∼E) Vancouver scar scale (VSS) score of the patients 
at every visit. V1: visit 1 (baseline), V2: visit 2 (2 weeks after 
applying multi-growth factor [MGF] cream), V3: visit 3 (6 weeks 
after applying MGF cream), V4: visit 4 (12 weeks after applying 
MGF cream). *Signifies statistically significant difference (p
＜0.05).
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Fig. 3. Photographs of a 48-year-old male patient taken at each visit. (A) Baseline (Vancouver scar scale [VSS] vascularity 1, pigmentation 
1, pliability 1, height 0), (B) 2 weeks after applying multi-growth factor (MGF) cream (VSS vascularity 0, pigmentation 0, pliability 
1, height 0), (C) 6 weeks after applying MGF cream (VSS vascularity 0, pigmentation 0, pliability 0, height 0), (D) 12 weeks after 
applying MGF cream (VSS vascularity 0, pigmentation 0, pliability 0, height 0). The post-thyroidectomy scar showed improvement 
after applying MGF cream.
Fig. 4. Overall satisfaction score after applying multi-growth 
factor cream. 
in Fig. 3.
In the subset analysis of VSS, the pigmentation score of 
the scar became significantly lower at 2 weeks (0.76±0.94 
vs. 0.19±0.68; p＜0.05), 6 weeks (0.76±0.94 vs. 0.05±0.22; 
p＜0.05), and 12 weeks (0.76±0.94 vs. 0; p＜0.05) com-
pared to the baseline, and the vascularity score of the scar 
also became significantly lower at 6 weeks (1.14±0.36 vs. 
0.81±0.40; p＜0.05) and 12 weeks (1.14±0.36 vs. 
0.76±0.44; p＜0.05) compared to the baseline. None of 
the patients using MGF cream showed hypertrophy during 
the 12 weeks of follow-up period.
Patient satisfaction
Twenty-one patients completed the study, and overall sat-
isfaction score was assessed at last visit, after applying 12 
weeks of MGF cream. Mean satisfactions score was 
2.19±0.68, which means majority of the patients were 
satisfied with the use of MGF cream and the percentage of 
patients who were very satisfied or satisfied was over 85% 
(18/21) (Fig. 4). There was no adverse event or discomfort 
associated with the use of the MGF-containing cream.
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DISCUSSION
Hypertrophic scar and keloid are skin abnormalities that 
are characterized by excessive deposition of collagen in 
the dermis and subcutaneous tissues resulting from un-
balanced tissue homeostasis during normal wound heal-
ing, which can sometimes cause cosmetic and functional 
impairment such as disfigurement, contractures, pruritus 
and pain6. 
Although there have been many options for treating hyper-
trophic scars such as intralesional corticosteroids, intrale-
sional 5-fluorouracil, cryotherapy, laser therapy and surgi-
cal excision, scar is irreversible and none of these treat-
ments can turn back the scar to previous state without 
leaving a trace7-9. Thus it is important to prevent or mini-
mize scar formation rather than treating developed scar late.
Early and effective treatment of scarring can prevent se-
vere scar change and the scarring that often follows. To 
minimize scarring, optimal environment for wound heal-
ing including proper circulation, nutrition and immune 
status is essential4. We try to protect wound from infection 
and support optimal moisture using a variety of dressing 
materials, silicone gel or sheet in case of necessity, how-
ever, these methods alone are not sufficient in effect4,10. 
A number of growth factors, such as transforming growth 
factor (TGF)-β, TGF-α, FGF, VEGF, PDGF, and EGF, play 
important roles in wound healing through autocrine, para-
crine, and endocrine processes11. These growth factors 
control many key cellular activities involved in the normal 
tissue repair process, including cell division, cell migra-
tion, angiogenesis, and synthesis of extracellular matrix 
components4. 
PDGF and EGF promote the wound healing cascade by 
activating and attracting neutrophils, macrophages, endo-
thelial cells, and fibroblasts12,13. Some growth factors, such 
as FGF, VEGF, and PDGF, act as angiogenic factors that 
stimulate endothelial cells and mediate neovascularization 
and vessel repair at the wound site. They are also im-
portant modulators of cell growth and differentiation14-16. 
In particular, EGF is secreted from platelets, keratinocytes, 
and macrophages during the wound healing process and 
activates tyrosine kinase by binding to the EGF receptor 
present in keratinocytes and fibroblasts17, which has been 
proven in numerous studies to promote wound healing by 
shortening the healing time and increasing the tissue ten-
sile strength by stimulating keratinocyte proliferation and 
acting on fibroblasts and smooth muscle cells18,19.
Further, there have been several studies that have exam-
ined the benefits of exogenous growth factor application 
for wound healing and scar. It was demonstrated that re-
combinant human EGF significantly reduces cutaneous 
scars by suppressing inflammatory reactions, decreasing 
TGF-β1 expression, and suppressing excessive collagen 
formation in a murine full-thickness wound healing model20.
In addition, recombinant human PDGF has been ap-
proved by the US Food and Drug Administration as a top-
ical growth factor for use on chronic diabetic neuropathic 
foot ulcers. It promotes the chemotactic recruitment and 
proliferation of cells involved in wound repair and in-
creases the probability that well-perfused, properly de-
brided diabetic foot ulcers will heal completely and in 
shorter times21,22. 
To date, silicone-based products such as silicone sheets 
and gels are widely used for scar prevention. A meta-anal-
ysis from Cochrane group showed that silicone gel sheet-
ing reduced the incidence of hypertrophic scarring in 
high-risk individuals compared with no treatment (response 
rate: 0.46; 95% confidence interval, 0.21∼0.98)23. The 
mechanism of action of silicone therapy has not been fully 
elucidated but occlusion and hydration of the stratum cor-
neum with subsequent cytokine-mediated signaling from 
keratinocytes to dermal fibroblasts are now universally ac-
cepted as the major mechanisms24. In vitro study has 
shown that the production of basic FGFs (bFGFs) can be 
increased by silicone products25. And in vivo study using 
immunohistochemistry has also showed that the expression 
of bFGF was significantly higher in the scar tissue follow-
ing the use of silicone gel sheeting compared with the un-
treated scar tissue26. The MGF cream contained many 
growth factors including FGF, so that it can be considered 
to share a common mechanism of action with the silicone 
gel sheeting in scar prevention. 
In our study, over 85% of the patients were satisfied with 
the use of MGF cream without showing any adverse 
effect. And the VSS scores and the results of the objective 
assessments demonstrated the improvement of overall scar 
quality. VSS scores were improved with the use of MGF 
cream especially in pigmentation and vascularity subsets. 
In objective assessments, the degree of pigmentation, the 
relative elasticity, and the skin hydration status showed 
improvement with the use of MGF cream. 
However, this study was performed only in the study 
group. Thus it is difficult to rule out the placebo effects, 
and this absence of the control group could be a limitation 
in this study. Nevertheless, the MGF cream might have ad-
ditive or supportive effect for scar formation after thyroi-
dectomy according to the results in this study. However, 
this should be clarified with further randomized controlled 
studies in the future, and studies comparing the efficacy 
between silicone gel sheeting and MGF cream or a combi-
nation of these products in scar management can be 
needed.
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